Roche Holding AG SG&A Expenses 2010-2023 | RHHBY

Roche Holding AG annual/quarterly sg&a expenses history and growth rate from 2010 to 2023. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
  • Roche Holding AG sg&a expenses for the quarter ending December 31, 2023 were $M, a NAN% increase year-over-year.
  • Roche Holding AG sg&a expenses for the twelve months ending December 31, 2023 were $0M, a NAN% increase year-over-year.
  • Roche Holding AG annual sg&a expenses for 2023 were $16.576B, a 26.24% increase from 2022.
  • Roche Holding AG annual sg&a expenses for 2022 were $13.13B, a 9.42% decline from 2021.
  • Roche Holding AG annual sg&a expenses for 2021 were $14.496B, a 7.74% increase from 2020.
Roche Holding AG Annual SG&A Expenses
(Millions of US $)
2023 $16,576
2022 $13,130
2021 $14,496
2020 $13,454
2019 $15,176
2018 $15,711
2017 $13,488
2016 $11,021
2015 $12,011
2014 $13,679
2013 $11,894
2012 $12,370
2011 $11,766
2010 $11,880
2009 $10,760
Roche Holding AG Quarterly SG&A Expenses
(Millions of US $)
2023-12-31
2023-06-30
2022-12-31
2022-06-30
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
2010-06-30
2009-12-31
2009-06-30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $247.847B $65.370B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.326B 79.06
Novo Nordisk (NVO) Denmark $377.087B 27.19
Johnson & Johnson (JNJ) United States $363.912B 15.13
AbbVie (ABBV) United States $309.709B 16.30
Merck (MRK) United States $248.613B 16.52
AstraZeneca (AZN) United Kingdom $217.852B 18.54
Novartis AG (NVS) Switzerland $210.389B 13.98
Pfizer (PFE) United States $150.855B 10.32
Sanofi (SNY) $132.349B 11.99
Bayer (BAYRY) Germany $22.242B 3.56
Innoviva (INVA) United States $1.183B 9.84